Skip to main content
SpringerLink
Log in

Eribulin mesylate in previously treated patients with advanced liposarcoma: a guide to its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Eribulin mesylate (Halaven®), a synthetic analogue of halichondrin B, is a welcome addition to the therapeutic options for treatment-refractory liposarcoma. It acts as a microtubule dynamics inhibitor, disrupting mitosis and leading to apoptotic cell death in cancer cells. Eribulin mesylate significantly improved overall and progression-free survival compared with dacarbazine and has a manageable tolerability profile in patients with unresectable, advanced liposarcoma whose disease has progressed following prior treatment, including an anthracycline-based regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Schoffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387(10028):1629–37.

    Article  CAS  PubMed  Google Scholar 

  2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guideline®): soft tissue sarcoma (version 2.2016). Fort Washington (PA): National Comprehensive Cancer Network, Inc.; 2016.

  3. The ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii102–12.

  4. Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: International Agency for Research on Cancer/World Health Organization; 2013.

    Google Scholar 

  5. Halaven 0.44 mg/ml solution for injection: summary of product characteristics. London: European Medicines Agency; 2016.

  6. Halaven (eribulin mesylate) injection, for intravenous use: US prescribing information. Woodcliff Lake (NJ): Eisai Inc.: 2016.

  7. Dybdal-Hargreaves NF, Risinger AL, Mooberry SL. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Clin Cancer Res. 2015;21(11):2445–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kawano S, Asano M, Adachi Y, et al. Antimitotic and non-mitotic effects of eribulin mesilate in soft tissue sarcoma. Anticancer Res. 2016;36(4):1553–61.

    CAS  PubMed  Google Scholar 

  9. Schoffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011;12(11):1045–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The article was reviewed by: L. Bergmann, Medical Clinic II, University Hospital Frankfurt, Frankfurt/Main, Germany; S. V. Sakpal, Department of Surgery, Saint Barnabas Medical Center, Livingston, NJ, USA; R. J. Young, Academic Unit of Oncology, Weston Park Hospital, Sheffield, UK.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Karly P. Garnock-Jones & Katherine A. Lyseng-Williamson

Authors
  1. Karly P. Garnock-Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K. P. Garnock-Jones and K. A. Lyseng-Williamson are salaried employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garnock-Jones, K.P., Lyseng-Williamson, K.A. Eribulin mesylate in previously treated patients with advanced liposarcoma: a guide to its use. Drugs Ther Perspect 32, 510–514 (2016). https://doi.org/10.1007/s40267-016-0356-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0356-8

Keywords

Search

Navigation